Ascend Vitality review

Ascend’s primary NAD⁺ offer is $179 for a one-month plan or $387 prepaid for the first three months. Older price blocks remain elsewhere, and the sermorelin address now leads to an educational guide rather than an own-plan quote. Terms require five business days before the next charge and generally make sales final, qualifying no-notice cancellation marketing.

Ascend Vitality LLC operates a weight-loss and wellness platform, separate from its independent clinicians and pharmacies. Its current catalog lists NAD⁺ injection, nasal NAD⁺ and glutathione cards. The sermorelin address redirects to an educational guide; that guide’s market-wide prices do not establish Ascend’s own treatment availability or quote.

The NAD⁺ page lists intake and a video visit, plus provider evaluation, shipping, messaging and dose adjustments without a membership fee. It also advertises included labs, while the terms permit separately billed labs unless checkout includes them. Obtain the program-specific lab and visit charges.

The contact page names Epiq Scripts, Southend Pharmacy, AbsoluteRX and Emerald Compounding Pharmacy as partners. These are seller disclosures, not your actual assignment or independent credential verification. The seller claims all 50 states and DC; confirm eligibility for your treatment.

The primary injectable NAD⁺ offer is $179 for a one-month plan or $387 for the first three months, displayed as a $129/month equivalent. The prepaid offer establishes the first period only; the next debit and prescribed supply need confirmation. Older catalog blocks still show $199. Nasal NAD⁺ has its own $179 monthly/$387 first-three-month offer alongside a legacy $149 block, so confirm the selected plan. Glutathione cards have inconsistent billing labels and the older product link returns an error; they do not establish a complete quote. No Ascend sermorelin plan price is confirmed.

Subscriptions renew automatically at the checkout amount and frequency. Cancellation must arrive by portal or email at least five business days before the next charge, despite no-notice cancellation marketing. Pausing is discretionary. The terms generally make sales final, make rendered clinical services non-refundable and exclude prescription returns once dispensed or shipped, subject to stated or legal exceptions. Shipping estimates depend on clinician and pharmacy processing and location.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The site describes pharmacy-compounded products; current pharmacy assignment and legacy peptide availability need confirmation. The FDA does not review compounded drugs for safety or effectiveness, and Ascend states as much. On the evidence, take the wellness line one compound at a time. Sermorelin's growth-hormone-axis effect is a real mechanism with thin long-term outcome data and no controlled trial behind the recovery and body-composition claims. Injectable and intranasal NAD⁺ have no controlled human outcome trials; the oral precursors NR and NMN are the studied forms and what they demonstrate is a raised blood NAD⁺ level, not an improved clinical outcome. Injectable glutathione has essentially no controlled human outcome evidence. Membership of a peptide trade association is a commercial affiliation and is not evidence about any of these compounds. Individual results vary.